Truist Lowers PT on DaVita Inc. (DVA), Keeps a Hold Rating

​DaVita Inc. (NYSE:DVA) is one of the Best 52-Week Low Mid Cap Stocks to Buy Now. On October 14, David MacDonald from Truist lowered the firm’s price target on DaVita Inc. (NYSE:DVA) from $148 to $140, while keeping a Hold rating on the stock.

​The analyst noted that they remain broadly bullish on the healthcare industry, driven by the ongoing core strength in demand. The firm noted they like the companies they cover based on their long-term positioning and the overall improved visibility around the regulatory environment. In addition, MacDonald also likes the strong free cash flow and financial flexibility of the sector in general.

​DaVita Inc. (NYSE:DVA) is a healthcare company specializing in kidney care services, primarily providing dialysis treatment for patients with chronic kidney failure and end-stage kidney disease in the United States.

While we acknowledge the potential of DVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.